<DOC>
	<DOCNO>NCT01072552</DOCNO>
	<brief_summary>The hypothesis present study prophylaxis palivizumab prevent severe RS virus infection infancy among preterm infant may reduce risk subsequent recurrent wheeze childhood . The infant bear July 1st December 31st 2007 gestational age 33 35 week enrol study end RS virus infection season , April 2008 . The infant unintentionally divide two group , either palivizumab treat untreated group enrollment , time palivizumab prophylaxis already end . The study infant follow age 3 record incidence either parent report physician diagnosed recurrent wheezing . The difference incidence recurrent wheeze group analyze Kaplan-Meier method .</brief_summary>
	<brief_title>Effect Palivizumab Later Recurrent Wheezing Preterm Infants</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Sounds</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Infants bear July ~ December 2007 33~35 week gestation Intrauterine growth retardation ( le 2.5SD ) Infants chronic lung disease ( CLD ) respiratory disease Infants receive mechanical ventilation . Infants chronic heart disease ( CHD ) congenital anomaly ( immunodeficiency ) . Infants receive less 3 dos palivizumab first 6 month life</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>recurrent wheeze</keyword>
	<keyword>asthma</keyword>
	<keyword>preterm infant</keyword>
	<keyword>palivizumab</keyword>
	<keyword>atopic disease</keyword>
</DOC>